ELI LILLY & Co
SEC EDGAR quarterly and annual company filings
Past bets that played out
These are the clearest thesis calls with observable outcomes, linked back to the original videos.
The provided excerpt is only the Form 10‑Q cover page for Eli Lilly (period ended 2026‑03‑31). It contains security identifiers (LLY and exchange-listed notes) and standard SEC filing compliance checkboxes, but no financial results, guidance, risk updates, or segment/drug performance details. As such, it does not support a directional equity or credit trade thesis by itself.
Excerpt is the Form 10-K cover page for Eli Lilly (fiscal year ended 2025-12-31). It primarily lists the company’s registered securities: common stock (LLY) and multiple exchange-listed note tickers (LLY26, LLY30, LLY31, LLY33, LLY36, LLY43, LLY49A, LLY51, LLY61). No operating/financial performance details or new guidance are included in the provided text, limiting market-actionable signal.
Excerpt is the cover/header of Eli Lilly’s Form 10‑Q for quarter ended 2025‑09‑30. It confirms SEC filing status and lists LLY common stock and multiple exchange-listed bond note tickers (LLY26, LLY30, LLY31, LLY33, LLY36, LLY43, LLY49A, LLY51, LLY61). No operating/financial results, guidance, risks, segment performance, or MD&A details are provided in the text shown, limiting actionable inference.
What this channel is watching now
Recent mentions show where this author is concentrating attention right now.
Latest videos and market context
Recent source posts from this author. Create an account to inspect the complete persisted research trail.
GEV 10-Q report for 2026-06-30
The provided excerpt is only the Form 10‑Q cover page for GE Vernova Inc. (GEV) for quarter ended 2026‑06‑30, with no financial statements, MD&A, segment results, guidance, backlog, risks, or other performance details included. As-is, it contains almost no trade-relevant incremental information beyond confirming the filing/period and listing details.
SNBR 10-Q report for 2026-04-04
This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
SOUN 10-Q report for 2026-03-31
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
WEAT 10-Q report for 2026-03-31
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
Proof-backed call history
These are recent thesis calls tied to original source content where available.
The provided excerpt is only the Form 10‑Q cover page for Eli Lilly (period ended 2026‑03‑31). It contains security identifiers (LLY and exchange-listed notes) and standard SEC filing compliance checkboxes, but no financial results, guidance, risk updates, or segment/drug performance details. As such, it does not support a directional equity or credit trade thesis by itself.
Excerpt is the Form 10-K cover page for Eli Lilly (fiscal year ended 2025-12-31). It primarily lists the company’s registered securities: common stock (LLY) and multiple exchange-listed note tickers (LLY26, LLY30, LLY31, LLY33, LLY36, LLY43, LLY49A, LLY51, LLY61). No operating/financial performance details or new guidance are included in the provided text, limiting market-actionable signal.
Excerpt is the cover/header of Eli Lilly’s Form 10‑Q for quarter ended 2025‑09‑30. It confirms SEC filing status and lists LLY common stock and multiple exchange-listed bond note tickers (LLY26, LLY30, LLY31, LLY33, LLY36, LLY43, LLY49A, LLY51, LLY61). No operating/financial results, guidance, risks, segment performance, or MD&A details are provided in the text shown, limiting actionable inference.
Provided text is only the cover/administrative portion of Eli Lilly’s (LLY) Form 10-Q for the quarter ended June 30, 2025. It lists exchange-registered securities (LLY common stock and several NYSE-listed notes) and indicates the company has filed required reports. No financial statements, guidance, segment updates, risk factors, pipeline/commercial commentary, or material events are included in the excerpt, so there is no clear trading catalyst to evaluate.
About this channel
Channel bio, source link, and public-market context from YouTube.
SEC EDGAR quarterly and annual company filings
Most recognized assets
Unlock the full track record
Create an account to inspect the complete author history, trust-weighted rankings, and persisted research across authors, theses, and assets.